ADA and lysosomal storage disease: The inclusion of ADA-SCID (adenosine deaminase-severe combined immunodeficiency) in expanded newborn screening by tandem mass spectrometry [21], as well as the expansion of the NBS programs to include lysosomal storage disorders (LSDS), could be the second target to achieve.